https://clinicaltrials.gov/ct2/show/NCT03427151?type=Intr&cond=Lupus&phase=012345&lupd_s=03%2F07%2F2019&lupd_d=14
Condition : Lupus Erythematosus, Systemic
Intervention : Drug: IPP-201101
Sponsor : ImmuPharma
Active, not recruiting
Study of Repeated Administration of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus
NCT03427151
Fri, 09 Feb 2018 12:00:00 EST
